Skip to content

Ketamine research published in 2024

Page 11 of 26: studies 201 to 220 of 518, newest first. Back to the ketamine overview

Studies

Innovative Ketamine Formulations: Enhancing Therapeutic Efficacy and Safety.

ACS Medicinal Chemistry Letters August 8, 2024 Robert B. Kargbo 1 citation

Ketamine, originally developed as an anesthetic, has shown significant potential for treating depression, chronic pain, and other conditions. However, its conventional formulations often result in side effects such as hallucinations and dizziness due to rapid spikes in blood concentration. This article explores recent patents that optimize ketamine delivery and efficacy: subcutaneous injectable...

DOI: 10.1021/acsmedchemlett.4c00330 (opens in new tab) Full text (opens in new tab) Ketamine-therapy Drug-delivery-systems Pharmaceutical-innovation Depression-treatment

REVOLUTIONIZING DEPRESSION TREATMENT: A PARADIGM SHIFT OF KETAMINE THERAPY – A SYSTEMATIC REVIEW

Asian Journal of Pharmaceutical and Clinical Research August 7, 2024 Yuvraj Kaushal, Pranav Goyal, Arshiya Sehgal

Objectives: Primary Objective: (1) The objectives of the study are as follows: assessment of the effectiveness of ketamine-based treatment in known patients of various subtypes of depression and (2) assessment of time of onset and duration along with routes of administration and safety of ketamine therapy. Secondary Objective: The objectives of the study are as follows: (1) evaluate changes in...

Non-improvement predicts subsequent non-response to repeated-dose intravenous ketamine for depression: a re-analysis of a 2-week open-label study in patients with unipolar and bipolar depression.

Translational Psychiatry August 6, 2024 Chengyu Wang, Xiaofeng Lan, Weijian Liu et al. 6 citations

There is insufficient evidence to guide dose and frequency optimization with repeated-dose ketamine for depression. This study assessed the value of symptomatic non-improvement after the first few ketamine infusions as a predictor of overall non-response in depression for early decision-making to discontinue treatment. A total of 135 individuals with major depressive disorder or bipolar...

DOI: 10.1038/s41398-024-03027-2 (opens in new tab) Full text (opens in new tab) Depression treatment Ketamine therapy Mental health research Treatment response prediction

LSD and ketamine in schizoaffective paranoid psychosis involving childhood and war trauma—a retrospective case study

August 5, 2024 Mika Turkia preprint

Currently, documentation on the effects of psychedelics on psychosis appears scarce. In the present case, a higher-dose LSD experience during acute paranoid psychosis before the initiation of antipsychotics induced feelings of love, which resolved the majority of the symptoms of the paranoid psychosis in one session, leading the person to reconnect with his family and seek treatment in a...

DOI: 10.31234/osf.io/5azpy (opens in new tab) Paranoia Psychosis Aripiprazole Antipsychotic +3

Evaluation of the Effects of Repetitive Anaesthesia Administration on the Brain Tissues and Cognitive Functions of Rats with Experimental Alzheimer's Disease.

Medicina (Kaunas, Lithuania) August 5, 2024 Nuray Camgoz Eryilmaz, Mustafa Arslan, Ayşegül Küçük et al. 3 citations

Introduction: We evaluated the effects of repeated ketamine, propofol, and ketamine + propofol administration on cognitive functions and brain tissue of elderly rat models with streptozotocin-induced Alzheimer's disease. Materials and Methods: Thirty elderly male Wistar Albino rats were divided into five groups: control (Group C), Alzheimer's (Group A), Alzheimer's + ketamine (Group AK),...

Low dose of esketamine after childbirth helps mothers at risk of depression

The Brown University Psychopharmacology Update August 1, 2024

Women with prenatal depressive symptoms who received a single low dose of esketamine shortly after childbirth showed a substantially lower incidence of a major depressive episode at 42 days postpartum than women receiving placebo, a new study has found. Neuropsychiatric adverse events occurred more frequently in the esketamine group, but no severe adverse events were reported.

Effects of intraoperative low-dose esketamine on postoperative pain after vestibular schwannoma resection: A prospective randomized, double-blind, placebo-controlled study.

British Journal of Clinical Pharmacology August 1, 2024 Kaizheng Chen, Yaming Xie, Songyuan Chi et al. 6 citations

Esketamine may reduce acute postoperative pain in several settings. However, the effects of low-dose esketamine on postoperative pain after vestibular schwannoma (VS) resection with propofol/remifentanil total intravenous anaesthesia (TIVA) are unclear. The aim of this study is to observe the effects of intraoperative low-dose esketamine on postoperative pain after vestibular schwannoma...

Ketamine-enhanced prolonged exposure therapy in veterans with PTSD: A randomized controlled trial protocol.

Contemporary Clinical Trials August 1, 2024 Paulo R Shiroma, Paul Thuras, Melissa A Polusny et al. 7 citations

The 2023 VA/DoD Clinical Practice Guideline for the Management of PTSD recommends individual, manualized trauma-focused such as Prolonged Exposure (PE) over pharmacologic interventions for the primary treatment of PTSD. Unfortunately, clinical trials of trauma-based therapies in the military and veteran population showed that 30% to 50% of patients did not demonstrate clinically meaningful...

DOI: 10.1016/j.cct.2024.107569 (opens in new tab) Full text (opens in new tab) Prolonged exposure PTSD-Treatment Veterans-mental-health Ketamine-therapy +2

Fluorodeschloroketamine found as a street drug in drug seizures and drug driving cases in Hong Kong.

Forensic Science International August 1, 2024 Wing-Chi Cheng, Kwok-Leung Dao, Wing-Cheong Wong 3 citations

With the decline of the use of ketamine, one of the common drugs of abuse in Hong Kong, detection of ketamine-related analogues in local laboratories has been encountered. A brief account of the occurrence of fluorodeschloroketamine (FDCK) in forensic cases is reported through a retrospective study of all drug seizures and driving under the influence of drugs (DUID) cases since its first...

DOI: 10.1016/j.forsciint.2024.112075 (opens in new tab) Full text (opens in new tab) Drug driving Drug seizures Fluorodeschloroketamine Fluorodeschloronorketamine +4

Effects of association between resveratrol and ketamine on behavioral and biochemical analysis in mice.

Journal of Neural Transmission August 1, 2024 Patrícia Zorzi Juliani, Talita Rodrigues, Getulio Nicola Bressan et al. 4 citations

Resveratrol (3,5,4'-trihydroxy-trans-stilbene), a phenol commonly found in grapes and wine, has been associated as protective in experimental models involving alterations in different neurotransmitter systems. However, studies are reporting that resveratrol could have adverse effects. This study evaluated if the association of a low dose of ketamine and resveratrol could induce behavioral...

DOI: 10.1007/s00702-024-02793-z (opens in new tab) Full text (opens in new tab) Il-6 Lipid peroxidation Locomotor activity Monoamine oxidase +6

Rapid and long-lasting effects of subcutaneous esketamine on suicidality: An open-label study in patients with treatment-resistant depression.

Journal of Psychiatric Research August 1, 2024 Eduardo Igor Torquato Cardoso Lopes, Patrícia Cavalcanti-Ribeiro, Fernanda Palhano-Fontes et al. 9 citations

Therapeutics for suicide management is limited, taking weeks to work. This open-label clinical trial with 18 treatment-resistant depressive patients tested subcutaneous esketamine (8 weekly sessions) for suicidality. We noted a rapid and enduring effect of subcutaneous esketamine, lasting from one week to six months post-treatment, assessed by the Beck Inventory for Suicidality (BSI). There was...

The Use of Ketamine for the Treatment of Anhedonia in Depression.

CNS Drugs August 1, 2024 Liliana Patarroyo-Rodriguez, Stefanie Cavalcanti, Jennifer L. Vande Voort et al. 13 citations

Anhedonia, a complex symptom rooted in deficits across reward processes, is primarily linked to depression and schizophrenia but transcends diagnostic boundaries across various mental disorders. Its presence correlates with poorer clinical outcomes, including an increased risk of suicide and diminished response to treatment. The neurobiological underpinnings of anhedonia remain incompletely...

Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.

European Neuropsychopharmacology August 1, 2024 Roger S McIntyre, Istvan Bitter, Jozefien Buyze et al. 30 citations

In ESCAPE-TRD (NCT04338321), esketamine nasal spray (NS) significantly increased the probability of remission at Week 8, and of being relapse-free through Week 32 after remission at Week 8, versus quetiapine extended release (XR) in patients with treatment resistant depression (TRD). Here, we explore the time course, burden and consequences of treatment emergent adverse events (TEAEs) in the...

Administration of low dose intranasal ketamine exerts a neuroprotective effect on whole brain irradiation injury model in wistar rats.

Radiation and environmental biophysics August 1, 2024 Gökhan Yaprak, Nilsu Çini, Özüm Büke Atasoy et al. 3 citations

Exposure to ionizing radiation leads to oxidative stress and neuroinflammation, resulting in neurocognitive impairments. Adverse effects are also associated with glutamate-induced excitotoxicity due to alterations in the composition of glutamate receptors. Ketamine, which is a noncompetitive NMDA glutamate receptor antagonist, has been stated to exert an impact on glutamatergic receptors. This...

DOI: 10.1007/s00411-024-01085-0 (opens in new tab) Full text (opens in new tab) Bdnf Brain injury Neuroinflammation Oxidative stress +9

Can mind-altering prescription medicines be safe? Lessons from ketamine and esketamine.

Clinical Toxicology August 1, 2024 Richard C. Dart 9 citations

Recent decades have witnessed an extraordinary global crisis of drug misuse. Although opioid analgesics receive the most attention, numerous other drugs have increased rates of misuse. Ketamine and esketamine offer a unique natural experiment to explore two medications that are similar pharmacologically but differ in their availability to users and in their regulation by government agencies....

Association Between Low-Dose Ketamine After Periacetabular and/or Femoral Osteotomy and Postoperative Opioid Requirements.

Orthopaedic journal of sports medicine August 1, 2024 Nicholas G Girardi, Sean Malin, Christopher Zielenski et al.

Previous studies have sought to determine the effect of inpatient ketamine therapy on postoperative pain in a variety of surgical specialties. To determine the effects of postoperative ketamine analgesia after periacetabular osteotomy (PAO) and/or derotational femoral osteotomy (DFO) on opioid requirements, pain, and discharge time. Cohort study; Level of evidence, 3. Prospective data were...

DOI: 10.1177/23259671241257260 (opens in new tab) Full text (opens in new tab) Morphine milligram equivalent Opioids Periacetabular osteotomy Postoperative pain +5

"K Cramps," Recurrent Abdominal Pain in a Patient with Chronic Ketamine Use: A Case Report.

Clinical Practice and Cases in Emergency Medicine August 1, 2024 Tucker Avra, Jesus Torres, Kumar Felipe Vasudevan et al. 2 citations

Medical and nonmedical ketamine use is increasing in the United States. This will likely lead to an increase in emergency department (ED) visits in individuals experiencing associated side effects. Physicians will need to be able to effectively recognize and manage ketamine-related complications. A 31-year-old male with a three-year history of inhalational, intramuscular, and intravenous...

DOI: 10.5811/cpcem.19431 (opens in new tab) Full text (opens in new tab) Ketamine abuse Chronic pain Drug-induced illness Emergency medicine +1

[Treatment of New Daily Persistent Headache With Esketamine: Report of One Case].

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae August 1, 2024 Li Zhang, Jiao He, Cheng-Hui Pi et al. 1 citation

New daily persistent headache (NDPH) is a kind of persistent headache that patients can identify the exact date of the sudden onset.It is one of the rare primary headaches difficult to be cured and may lead to disability,seriously affecting the daily life and work.The exact pathogenesis of NDPH remains unclear,which makes the treatment difficult.Here we report a case of refractory NDPH treated...

DOI: 10.3881/j.issn.1000-503X.15842 (opens in new tab) Full text (opens in new tab) Deep brain stimulation Headache therapy Headache management Esketamine ketamine +4

Intravenous Sedation and Analgesia in a Pediatric Emergency Department: A Retrospective Descriptive Study.

Cureus August 1, 2024 Madalena Carvalho, Ana Teresa Guerra, Marta Moniz et al.

Background Painful procedures in the pediatric emergency department often require the use of sedation and analgesia to ensure adequate pain control, a right of children and adolescents. This study aims to describe the procedural sedation and analgesia with intravenous medications performed in a pediatric emergency department. Methods This is a retrospective descriptive study of intravenous...

The Resistant Depression Response to Esketamine Assessing Metabolomics (ReDREAM) Project-Untargeted Metabolomics to Identify Biomarkers of Treatment Response to Intranasal Esketamine in Individuals with Treatment-Resistant Depression: A Study Protocol.

Alpha psychiatry August 1, 2024 Francesco Bartoli, Daniele Cavaleri, Ilaria Riboldi et al. 4 citations

Treatment-resistant depression (TRD) affects around 20-30% of people with major depressive disorder. In 2019, esketamine nasal spray was approved for TRD by both the US Food and Drug Administration and the European Medicines Agency. While its clinical efficacy and safety are proven, the mechanisms underlying its antidepressant effect remain unclear. The use of metabolomics may allow...